+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Breast Cancer Screening Market, Global Forecast by Screening Test, Population, Countries, Company Analysis

  • ID: 5024114
  • Report
  • May 2020
  • Region: Global
  • 380 pages
  • Renub Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AstraZeneca
  • Bayer AG
  • Novartis
  • Pfizer
  • Sanofi
  • MORE

Globally, breast cancer is considered one of the most common cancers in women around the world. Breast cancer is also a leading cause of death from cancer in the world's least developed nations. Every year 1.7 million new cases are diagnosed with breast cancer, and approximately 60% of deaths due to breast cancer occur around the world. Breast cancer is a form of cancer that occurs in the tissue of the breast. Formations of a lump in a breast and red patches on the skin are some of the typical breast cancer signs. Obesity, lack of physical activity, overexposure to radiation, and consuming alcohol are among the risk factors for breast cancer growth. According to the report, the Global Breast Cancer Screening Market is anticipated to reach US$ 51.8 Billion by the end of the year 2026, with double-digit CAGR during the forecast period.

COVID-19 impact on Breast Cancer Screening Market Worldwide

The COVID-19 outbreak could have an impact on all drug companies manufacturing, supply chain, and clinical trial operations. In the year 2020, the global breast cancer screening population, as well as the market, will decline. The primary reason for this decline is a coronavirus. For a complete analysis, read our report as to how COVID - 19 is affecting every quarter of the year 2020 and when the market will revive? Other challenges of breast cancer screening are high medication costs, therapy-related adverse effects, and lengthy product approval times are responsible for curbing market growth.

Growth Factors for Global Breast Cancer Screening Market

The key growth factors of the breast cancer market are the increasing number of females suffering from breast cancer, growing older women population is the primary factor for the growth of the market. In addition to this adoption of an unhealthy lifestyle, the rise of the female geriatric population, exposure to harmful radiation, and increased policy measures have contributed to market growth.

Also, the incidence of breast cancer is rising in the lower-income countries due to an increase in life expectancy, adaption to increasing urbanization and western lifestyles. World over, more than half of the breast cancer cases now have been reported from low and middle-income countries (LMICs) as these countries do not have proper breast screening programs; hence, the majority of cases are diagnosed in late stages. Growing breast cancer incidences & mortality in the low and middle-income countries, these countries need to develop an effective breast cancer screening program strategy that will address the earlier deduction of incidence of breast cancer for women.

Some of the major breast cancer screening technologies which help to find breast cancer after diagnosis are as follows. Breast cancer screening technologies are MRI, Ultrasound, and mammography screening. Mammography screening aims at minimizing the death rate from breast cancer by identifying unsuspected breast cancers early. The breast cancer mammography screening market is flourishing, driven by advances in technologies and delivery models, product innovations, increasing use of digital mammography equipment, and growing public awareness. Globally, awareness about breast cancer is increasing, with more women coming forward for their yearly mammograms after the age of 40 years.

Besides, around the world, governments have introduced screening programs for early detection that entails a routine check-up. Several countries are already offering breast cancer screening programs for women, and the number is establishing these programs are steadily increasing. In Germany, for example, the “Mammo Screening” program exists since 2002. In the United States, most states are introducing laws requiring health insurance companies to reimburse all or part of the cost of screening mammograms. Furthermore, the NHS Breast Screening Program in the United Kingdom provides free breast screening every three years for all women aged. Also, continuous efforts are taken by various government agencies and NGOs, the worldwide market for breast cancer screening.

This latest study report “Breast Cancer Screening Market, Population, by Screening Tests [Mammography, Magnetic Resonance Imaging (MRI) & Ultrasound] Countries (United States, Canada, France, United Kingdom, Germany, Italy, Spain, Netherlands, Norway, Switzerland, China, India, Korea, Japan, Singapore, Thailand, Malaysia, Brazil, Australia, New Zealand, South Africa, United Arab Emirates, Saudi Arabia), Company Analysis (AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG)” provides a detailed and comprehensive insight of the Breast Cancer Screening Market.

Screening Tests - Mammography is the Most Common Test for Breast Cancer Screening

Mammography is a sophisticated medical imaging that uses a low-dose x-ray device to view human breasts indoors. Mammography plays a vital role in the early detection and treatment of women with breast diseases. Breast Magnetic Resonance Imaging (MRI) or breast ultrasound, in addition to mammography, also helps detect breast cancer in women.

Countries - Total 23 Countries Market & Population for Breast Cancer Screening, Mammography Screening, MRI Screening & Ultrasound Screening has been studied in the report

The study includes a comprehensive Breast cancer overview of Canada, France, Italy, Spain, Switzerland, Netherlands, Norway, India, Australia, Japan, Korea, Singapore, Thailand, Malaysia, Brazil, New Zealand, South Africa, United Arab Emirates and Saudi Arabia Breast Cancer, Mammography, Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population and Market.

The report provides a complete analysis of the key Growth Drivers, Challenges, Market, Screened Population, and their projections for the upcoming years till 2026.

All the companies have been studied from two points

  • Recent Developments
  • Sales Analysis

Company Analysis

  • AstraZeneca
  • Novartis
  • Sanofi
  • Pfizer
  • Bayer AG

Breast Cancer Screening Market & Population - by Screening Tests Covered in the Report

  • Mammography
  • Magnetic Resonance Imaging (MRI)
  • Ultrasound

23 Regions Covered in the Report:

1. United States
2. Canada
3. United Kingdom
4. France
5. Germany
6. Italy
7. Spain
8. Netherlands
9. Norway
10. Switzerland
11. India
12. China
13. Japan
14. Korea
15. Singapore
16. Thailand
17. Malaysia
18. Brazil
19. Australia
20. New Zealand
21. South Africa
22. United Arab Emirates
23. Saudi Arabia

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bayer AG
  • Novartis
  • Pfizer
  • Sanofi
  • MORE

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Global Breast Cancer Screening Population
4.1 Mammography Screening Population
4.2 MRI & Ultrasound Screening Population

5. Global Breast Cancer Screening Market
5.1 Mammography Screening Market
5.2 Magnetic Resonance Imaging (MRI) Screening Market
5.3 Ultrasound Screening Market

6. Population Share - Global Breast Cancer Screening
6.1 Breast Cancer Screening
6.2 Mammography Screening
6.3 MRI & Ultrasound Screening

7. Market Share - Global Breast Cancer Screening
7.1 Breast Cancer Screening
7.2 Mammography Screening
7.3 MRI Screening
7.4 Ultrasound Screening

8. United Kingdom - Breast Cancer Screening Population & Market
8.1 United Kingdom Breast Cancer Screening Population & Forecast
8.1.1 Mammography Screening Population
8.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
8.2 United Kingdom Breast Cancer Screening Market & Forecast
8.2.1 Mammography Screening Market
8.2.2 Magnetic Resonance Imaging (MRI) Screening Market
8.2.3 Ultrasound Screening Market

9. France - Breast Cancer Screening Population & Market
9.1 France Breast Cancer Screening Population & Forecast
9.1.1 Mammography Screening Population
9.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
9.2 France Breast Cancer Screening Market & Forecast
9.2.1 Breast Cancer Mammography Screening Market
9.2.2 Magnetic Resonance Imaging (MRI) Screening Market
9.2.3 Ultrasound Screening Market

10. Germany - Breast Cancer Screening Population & Market
10.1 Germany Breast Cancer Screening Population & Forecast
10.1.1 Mammography Screening Population
10.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
10.2 Germany Breast Cancer Screening Market & Forecast
10.2.1 Breast Cancer Mammography Screening Market
10.2.2 Magnetic Resonance Imaging (MRI) Screening Market
10.2.3 Ultrasound Screening Market

11. Italy - Breast Cancer Screening Population & Market
11.1 Italy Breast Cancer Screening Population & Forecast
11.1.1 Mammography Screening Population
11.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
11.2 Italy Breast Cancer Screening Market & Forecast
11.2.1 Mammography Screening Market
11.2.2 Magnetic Resonance Imaging (MRI) Screening Market
11.2.3 Ultrasound Screening Market

12. Spain - Breast Cancer Screening Population & Market
12.1 Spain Breast Cancer Screening Population & Forecast
12.1.1 Mammography Screening Population
12.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
12.2 Spain Breast Cancer Screening Market & Forecast
12.2.1 Mammography Screening Market
12.2.2 Magnetic Resonance Imaging (MRI) Screening Market
12.2.3 Ultrasound Screening Market

13. Switzerland - Breast Cancer Screening Population & Market
13.1 Switzerland Breast Cancer Screening Population & Forecast
13.1.1 Mammography Screening Population
13.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
13.2 Switzerland Breast Cancer Screening Market & Forecast
13.2.1 Mammography Screening Market
13.2.2 Magnetic Resonance Imaging (MRI) Screening Market
13.2.3 Ultrasound Screening Market

14. Norway - Breast Cancer Screening Population & Market
14.1 Norway Breast Cancer Screening Population & Forecast
14.1.1 Mammography Screening Population
14.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
14.2 Norway Breast Cancer Screening Market & Forecast
14.2.1 Mammography Screening Market
14.2.2 Magnetic Resonance Imaging (MRI) Screening Market
14.2.3 Ultrasound Screening Market

15. Netherlands - Breast Cancer Screening Population & Market
15.1 Netherlands Breast Cancer Screening Population & Forecast
15.1.1 Mammography Screening Population
15.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
15.2 Netherlands Breast Cancer Screening Market & Forecast
15.2.1 Mammography Screening Market
15.2.2 Magnetic Resonance Imaging (MRI) Screening Market
15.2.3 Ultrasound Screening Market

16. United States - Breast Cancer Screening Population & Market
16.1 United States Breast Cancer Screening Population & Forecast
16.1.1 Mammography Screening Population
16.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
16.2 United States Breast Cancer Screening Market & Forecast
16.2.1 Mammography Screening Market
16.2.2 Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market
16.2.3 Ultrasound Screening Market

17. Canada - Breast Cancer Screening Population & Market
17.1 Canada Breast Cancer Screening Population & Forecast
17.1.1 Mammography Screening Population
17.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
17.2 Canada Breast Cancer Screening Market & Forecast
17.2.1 Mammography Screening Market
17.2.2 Magnetic Resonance Imaging (MRI) Screening Market
17.2.3 Ultrasound Screening Market

18. Japan - Breast Cancer Screening Population & Market
18.1 Japan Breast Cancer Screening Population & Forecast
18.1.1 Mammography Screening Population
18.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
18.2 Japan Breast Cancer Screening Market & Forecast
18.2.1 Mammography Screening Market
18.2.2 Magnetic Resonance Imaging (MRI) Screening Market
18.2.3 Ultrasound Screening Market

19. Korea - Breast Cancer Screening Population & Market
19.1 Korea Breast Cancer Screening Population & Forecast
19.1.1 Mammography Screening Population
19.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
19.2 Korea Breast Cancer Screening Market & Forecast
19.2.1 Mammography Screening Market
19.2.2 Magnetic Resonance Imaging (MRI) Screening Market
19.2.3 Ultrasound Screening Market

20. Singapore - Breast Cancer Screening Population & Market
20.1 Singapore Breast Cancer Screening Population & Forecast
20.1.1 Mammography Screening Population
20.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
20.2 Singapore Breast Cancer Screening Market & Forecast
20.2.1 Mammography Screening Market
20.2.2 Resonance Imaging (MRI) Screening Market
20.2.3 Ultrasound Screening Market

21. Malaysia - Breast Cancer Screening Population & Market
21.1 Malaysia Breast Cancer Screening Population & Forecast
21.1.1 Mammography Screening Population
21.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
21.2 Malaysia Breast Cancer Screening Market & Forecast
21.2.1 Mammography Screening Market
21.2.2 Magnetic Resonance Imaging (MRI) Screening Market
21.2.3 Ultrasound Screening Market

22. India - Breast Cancer Screening Population & Market
22.1 India Breast Cancer Screening Population & Forecast
22.1.1 Mammography Screening Population
22.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
22.2 India Breast Cancer Screening Market & Forecast
22.2.1 Mammography Screening Market
22.2.2 Magnetic Resonance Imaging (MRI) Screening Market
22.2.3 Ultrasound Screening Market

23. China - Breast Cancer Screening Population & Market
23.1 China Breast Cancer Screening Population & Forecast
23.1.1 Mammography Screening Population
23.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
23.2 China Breast Cancer Screening Market & Forecast
23.2.1 Mammography Screening Market
23.2.2 Magnetic Resonance Imaging (MRI) Screening Market
23.2.3 Ultrasound Screening Market

24. Thailand - Breast Cancer Screening Population & Market
24.1 Thailand Breast Cancer Screening Population & Forecast
24.1.1 Mammography Screening Population
24.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
24.2 Thailand Breast Cancer Screening Market & Forecast
24.2.1 Mammography Screening Market
24.2.2 Magnetic Resonance Imaging (MRI) Screening Market
24.2.3 Ultrasound Screening Market

25. Brazil - Breast Cancer Screening Population & Market
25.1 Brazil Breast Cancer Screening Population & Forecast
25.1.1 Mammography Screening Population
25.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
25.2 Brazil Breast Cancer Screening Market & Forecast
25.2.1 Mammography Screening Market
25.2.2 Magnetic Resonance Imaging (MRI) Screening Market
25.2.3 Ultrasound Screening Market

26. Australia - Breast Cancer Screening Population & Market
26.1 Australia Breast Cancer Screening Population & Forecast
26.1.1 Mammography Screening Population
26.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
26.2 Australia Breast Cancer Screening Market & Forecast
26.2.1 Mammography Screening Market
26.2.2 Magnetic Resonance Imaging (MRI) Screening Market
26.2.3 Ultrasound Screening Market

27. New Zealand - Breast Cancer Screening Population & Market
27.1 New Zealand Breast Cancer Screening Population & Forecast
27.1.1 Mammography Screening Population
27.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
27.2 New Zealand Breast Cancer Screening Market & Forecast
27.2.1 Mammography Screening Market
27.2.2 Magnetic Resonance Imaging (MRI) Screening Market
27.2.3 Ultrasound Screening Market

28. South Africa - Breast Cancer Screening Population & Market
28.1 South Africa Breast Cancer Screening Population & Forecast
28.1.1 Mammography Screening Population
28.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
28.2 South Africa Breast Cancer Screening Market & Forecast
28.2.1 Mammography Screening Market
28.2.2 Magnetic Resonance Imaging (MRI) Screening Market
28.2.3 Ultrasound Screening Market

29. United Arab Emirates - Breast Cancer Screening Population & Market
29.1 United Arab Emirates Breast Cancer Screening Population & Forecast
29.1.1 Mammography Screening Population
29.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
29.2 United Arab Emirates Breast Cancer Screening Market & Forecast
29.2.1 Mammography Screening Market
29.2.2 Magnetic Resonance Imaging (MRI) Screening Market
29.2.3 Ultrasound Screening Market

30. Saudi Arabia - Breast Cancer Screening Population & Market
30.1 Saudi Arabia Breast Cancer Screening Population & Forecast
30.1.1 Mammography Screening Population
30.1.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
30.2 Saudi Arabia Breast Cancer Screening Market & Forecast
30.2.1 Mammography Screening Market
30.2.2 Magnetic Resonance Imaging (MRI) Screening Market
30.2.3 Ultrasound Screening Market

31. Growth Drivers
31.1 Increasing Women’s Breast Cancer Care
31.2 Growing Breast Cancer Cases
31.3 Reclassification of Mammography Equipment by FDA

32. Breast Cancer Screening Market Challenges
32.1 Difference of Opinion on Breast Cancer Mammography Screening
32.2 Societal and Cultural Barriers for Breast Cancer Screening

33. Company Analysis
33.1 AstraZeneca
33.1.1 Resent Development
33.1.2 Revenue
33.2 Novartis
33.2.1 Resent Development
33.2.2 Revenue
33.3 Sanofi
33.3.1 Resent Development
33.3.2 Revenue
33.4 Pfizer
33.4.1 Resent Development
33.4.2 Revenue
33.5 Bayer AG
33.5.1 Resent Development
33.5.2 Revenue

Note: Product cover images may vary from those shown
3 of 4
  • AstraZeneca
  • Novartis
  • Sanofi
  • Pfizer
  • Bayer AG
Note: Product cover images may vary from those shown
4 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll